EP
MYGN icon

Eudaimonia Partners’s Myriad Genetics MYGN Stock Holding History

Eudaimonia Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$217K Buy
+6,732
New +$224K 0.04% 355
2021
Q2 		– Sell
-521
Closed -$16K – 997
2021
Q1 		$16K Buy
+521
New +$14.8K ﹤0.01% 1023

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Eudaimonia Partners's MYGN Position: Q3 2021 in Review

Eudaimonia Partners opened a new position in Myriad Genetics (MYGN) in Q3 2021: 6,732 shares worth $217K. The stake represents 0.04% of the portfolio and ranks #355 among its holdings. This is a return to the name: Eudaimonia Partners previously reported a position in MYGN as recently as Q1 2021.

Eudaimonia Partners first reported a position in MYGN in Q1 2021 and has held it in 2 quarters since. 213 funds tracked by Wall St. Rank hold MYGN as of Q3 2021.

  • Eudaimonia Partners held 6,732 shares of Myriad Genetics worth $217K as of Q3 2021.
  • Myriad Genetics was a new Eudaimonia Partners position in Q3 2021.
  • Myriad Genetics made up 0.04% of Eudaimonia Partners's portfolio in Q3 2021, its #355 holding.
  • Eudaimonia Partners first reported a position in Myriad Genetics in Q1 2021 and has held it in 2 quarters since.
  • 213 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2021.

Based on Eudaimonia Partners's 13F filing for Q3 2021, filed 25 Oct 2021.